Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer
14 June 2022 - 9:05PM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), today announced
the appointment of Susan L. Coultas, Ph.D., as Chief Clinical
Officer. In this role, Dr. Coultas serves as a member of the
executive team and has overall responsibility for planning the
initiation and execution of Clearside’s clinical trials, including
oversight of all clinical development operations.
“We are very excited to have Susan join our
team,” said George Lasezkay, Pharm.D., J.D., Clearside’s President
and Chief Executive Officer. “With her broad experience in clinical
development at multiple leading ophthalmic companies, she will make
significant contributions to Clearside’s vision, strategy, and
operational effectiveness. Her expertise in advancing a therapy
from the initial clinical development stages through approval for
commercialization will be a valuable asset as we continue to
progress our lead candidate, CLS-AX (axitinib injectable
suspension) in patients with neovascular age-related macular
degeneration (wet AMD). Dr. Thomas Ciulla, our Chief Medical
Officer and Chief Development Officer, will continue his current
responsibilities for clinical trial design and overall product
pipeline strategy and development. Tom will work closely with Susan
regarding the implementation and analysis of our clinical pipeline
programs.”
“I am pleased to join a dedicated team focused
on developing a new generation of impactful treatments for retinal
diseases utilizing a proven approach with our suprachoroidal space
injection platform,” said Susan L. Coultas, Ph.D., Chief Clinical
Officer. “I look forward to working with the executive team and
supporting our clinical programs to realize the broad potential of
our pipeline to benefit patients with sight-threatening eye
diseases.”
Dr. Coultas brings 35 years of experience in
clinical development in the biopharmaceutical industry. Most
recently, she served as Senior Vice President of Clinical
Development at Kala Pharmaceuticals, where she was responsible for
the planning and execution of its clinical programs, resulting in
two new drug application filings and product approvals. Dr. Coultas
has worked with multiple ophthalmic companies, both internally and
as a consultant, including Alcon Laboratories, Inc., CibaVision
Ophthalmics, Sucampo Pharmaceuticals, and Bausch+Lomb, Inc. Earlier
in her career, as owner of InfoQuest Clinical Network, Inc., Dr.
Coultas successfully identified, developed, and led a large network
of clinical research professionals that managed numerous clinical
trials in multiple systemic and ophthalmic therapeutic areas. Dr.
Coultas earned a Ph.D. in Public Health, Epidemiology, from Walden
University, a M.S. in Biology from University of North Texas, and a
B.S. in Biology from Texas Wesleyan University.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
proprietary SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector and strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. Clearside’s first product, XIPERE®
(triamcinolone acetonide injectable suspension) for suprachoroidal
use, is commercially available in the U.S. For more information,
please visit www.clearsidebio.com.
Cautionary Note Regarding
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe”, “expect”, “may”, “plan”,
“potential”, “will”, and similar expressions, and are based on
Clearside’s current beliefs and expectations. These forward-looking
statements include statements regarding the clinical development of
Clearside’s product candidates, including CLS-AX. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Risks
and uncertainties that may cause actual results to differ
materially include uncertainties inherent in the conduct of
clinical trials, Clearside’s reliance on third parties over which
it may not always have full control, uncertainties regarding the
COVID-19 pandemic and other risks and uncertainties that are
described in Clearside’s Annual Report on Form 10-K for the year
ended December 31, 2021, filed with the U.S. Securities and
Exchange Commission (SEC) on March 11, 2022, and Clearside’s other
Periodic Reports filed with the SEC. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to Clearside as of the date of this release,
and Clearside assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor and Media Contacts:Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2024 to May 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From May 2023 to May 2024